TrialBMJ open2025

Minimum clinically important difference in Quantitative Lung Fibrosis score associated with all-cause mortality in idiopathic pulmonary fibrosis: subanalysis from two phase II trials of pamrevlumab.

Grace Hyun Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.